Elite Pharmaceuticals Inc (ELTP) stock
ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 14/30
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026Market cap $281.77MP/E 5.0Yield –
Elite Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Elite Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was $37.81M, down 13.0% year over year. For fiscal 2026 it was $50.18M, up 141.0% from the year before. The highest annual figure on record is $50.18M in fiscal 2026.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $50.18M | +141.0% |
| FY2025 | Mar 31, 2025 | $20.83M | +72.0% |
| FY2024 | Mar 31, 2024 | $12.11M | +144.5% |
| FY2023 | Mar 31, 2023 | $4.95M | -21.1% |
| FY2022 | Mar 31, 2022 | $6.28M | +83.7% |
| FY2021 | Mar 31, 2021 | $3.42M | – |
| FY2020 | Mar 31, 2020 | -$965.61K | – |
| FY2019 | Mar 31, 2019 | -$7.90M | – |
| FY2018 | Mar 31, 2018 | -$8.05M | – |
| FY2017 | Mar 31, 2017 | -$6.64M | – |
| FY2016 | Mar 31, 2016 | -$7.65M | – |
| FY2015 | Mar 31, 2015 | -$15.93M | – |
| FY2014 | Mar 31, 2014 | -$4.83M | – |
| FY2013 | Mar 31, 2013 | -$1.14M | – |
| FY2012 | Mar 31, 2012 | -$1.48M | – |
| FY2011 | Mar 31, 2011 | -$402.29K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $10.31M | +19.7% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $7.78M | -64.6% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $10.44M | -8.8% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $9.28M | +557.9% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $8.61M | +131.9% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $21.98M | +424.9% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $11.44M | +182.1% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $1.41M | -63.6% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $3.71M | +64.8% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $4.19M | +116.9% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $4.06M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $3.88M | +70.2% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $2.25M | +60.8% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $1.93M | +46.3% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$42.81K | -103.7% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $2.28M | +7.0% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $1.40M | -18.6% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $1.32M | +3.2% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $1.15M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $2.13M | +60.0% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $1.72M | +2.8% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $1.28M | +10.3% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$744.52K | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $1.33M | +31.1% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $1.67M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $1.16M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$1.05M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $1.01M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$122.85K | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$816.75K | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$1.70M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$2.32M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$2.29M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$1.55M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$2.33M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$1.83M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$1.95M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$2.05M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$2.98M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -$1.70M | – |
See a number that looks wrong?